PE20200844A1 - Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x - Google Patents
Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides xInfo
- Publication number
- PE20200844A1 PE20200844A1 PE2020000355A PE2020000355A PE20200844A1 PE 20200844 A1 PE20200844 A1 PE 20200844A1 PE 2020000355 A PE2020000355 A PE 2020000355A PE 2020000355 A PE2020000355 A PE 2020000355A PE 20200844 A1 PE20200844 A1 PE 20200844A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxyl
- amino acid
- bile acids
- farnesoid
- receptor modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS 11-HIDROXILO DE ACIDOS BILIARES DE FORMULA (I) O UN CONJUGADO DE AMINOACIDO FARMACEUTICAMENTE ACEPTABLE DEL MISMO DONDE R1 ES HIDROXILO; R2, R3, R4, R5 Y R6 SON TAL COMO SE DEFINEN EN LA DESCRIPCION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR X FERNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, HEPATICA CRONICA, METABOLICA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823169P | 2013-05-14 | 2013-05-14 | |
| PCT/EP2014/059896 WO2014184271A1 (en) | 2013-05-14 | 2014-05-14 | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200844A1 true PE20200844A1 (es) | 2020-08-18 |
Family
ID=50721801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000355A PE20200844A1 (es) | 2013-05-14 | 2014-05-14 | Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x |
| PE2015002397A PE20160665A1 (es) | 2013-05-14 | 2014-05-14 | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002397A PE20160665A1 (es) | 2013-05-14 | 2014-05-14 | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US9611289B2 (es) |
| EP (4) | EP3848038B1 (es) |
| JP (2) | JP6326131B2 (es) |
| KR (1) | KR102229952B1 (es) |
| CN (2) | CN108245523B (es) |
| AU (1) | AU2014267324B2 (es) |
| BR (1) | BR112015028399B1 (es) |
| CA (1) | CA2912139C (es) |
| CL (2) | CL2015003344A1 (es) |
| CR (1) | CR20150643A (es) |
| CY (1) | CY1122614T1 (es) |
| DK (4) | DK3360881T3 (es) |
| EA (1) | EA030152B1 (es) |
| ES (4) | ES2843737T3 (es) |
| GT (1) | GT201500324A (es) |
| HR (1) | HRP20180931T1 (es) |
| HU (1) | HUE037996T2 (es) |
| IL (2) | IL242555B (es) |
| LT (1) | LT2997035T (es) |
| MA (1) | MA38647B1 (es) |
| ME (1) | ME03082B (es) |
| MX (1) | MX352065B (es) |
| MY (1) | MY187886A (es) |
| NI (1) | NI201500160A (es) |
| PE (2) | PE20200844A1 (es) |
| PH (1) | PH12015502576B1 (es) |
| PL (3) | PL2997035T3 (es) |
| PT (3) | PT2997035T (es) |
| RS (1) | RS57372B1 (es) |
| SA (1) | SA515370140B1 (es) |
| SG (1) | SG11201509352XA (es) |
| SI (3) | SI3360882T1 (es) |
| SM (1) | SMT201800326T1 (es) |
| TN (1) | TN2015000497A1 (es) |
| TR (1) | TR201809041T4 (es) |
| UA (1) | UA118673C2 (es) |
| WO (1) | WO2014184271A1 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138390B2 (en) | 2001-03-12 | 2006-11-21 | Intercept Pharmaceuticals | Steroids as agonists for FXR |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PT2997035T (pt) | 2013-05-14 | 2018-07-18 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| CN106661079B (zh) | 2014-05-29 | 2019-03-01 | 巴尔制药有限公司 | 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物 |
| KR20170094184A (ko) | 2014-11-06 | 2017-08-17 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| CN107108688B (zh) | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 |
| PL3221332T3 (pl) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr |
| US20170327531A1 (en) | 2014-11-19 | 2017-11-16 | NZP UK Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| CN107207559B (zh) | 2014-11-19 | 2019-10-25 | Nzp英国有限公司 | 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇 |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| KR20170099909A (ko) | 2014-11-26 | 2017-09-01 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| MA41094A (fr) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
| TN2017000344A1 (en) * | 2015-02-06 | 2019-01-16 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
| WO2016130809A1 (en) | 2015-02-11 | 2016-08-18 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| CA2978916A1 (en) * | 2015-03-09 | 2016-09-15 | Intercept Pharmaceuticals, Inc. | Methods for modulating bone density |
| CN107531741A (zh) | 2015-03-10 | 2018-01-02 | 美莱斯股份有限公司 | 氟化和烷基化胆酸 |
| AU2016233579A1 (en) * | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| ES2886766T3 (es) | 2015-03-31 | 2021-12-20 | Enanta Pharm Inc | Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos |
| MX2017012893A (es) | 2015-04-07 | 2018-01-15 | Intercept Pharmaceuticals Inc | Composiciones farmaceuticas para terapias combinadas. |
| WO2016168553A1 (en) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Deuterated obeticholic acid |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CN106478759A (zh) * | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN108348543A (zh) * | 2015-09-21 | 2018-07-31 | 英特塞普特医药品公司 | 促进肝再生的方法 |
| MA45761A (fr) * | 2015-10-07 | 2021-04-21 | Intercept Pharmaceuticals Inc | Modulateurs du récepteur farnésoïde x |
| MY196292A (en) * | 2016-01-28 | 2023-03-24 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Steroid Derivative Fxr Agonist |
| WO2017147174A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| WO2017147137A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| CA3016875C (en) * | 2016-03-11 | 2023-08-22 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| CN109071452A (zh) * | 2016-04-13 | 2018-12-21 | 英特塞普特医药品公司 | 治疗癌症的方法 |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| CN110121347A (zh) | 2016-11-29 | 2019-08-13 | 英安塔制药有限公司 | 制备磺酰脲胆汁酸衍生物的方法 |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
| JP2020509001A (ja) * | 2017-02-23 | 2020-03-26 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸誘導体及びマイクロバイオームの医薬組成物並びにその使用 |
| ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
| EP3606533B1 (en) | 2017-04-07 | 2023-11-15 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| WO2018226724A1 (en) * | 2017-06-05 | 2018-12-13 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of diabetic eye diseases with a bile acid derivatives |
| US11066437B2 (en) * | 2017-06-23 | 2021-07-20 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| EP3658150A4 (en) | 2017-07-24 | 2021-03-31 | Intercept Pharmaceuticals, Inc. | Isotopically labeled gallic acid derivatives |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN109182451B (zh) * | 2018-08-21 | 2021-06-11 | 四川大学 | 细胞色素cyp3a7酶的新型特异性探针反应及其应用 |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| KR20220016146A (ko) | 2019-05-30 | 2022-02-08 | 인터셉트 파마슈티컬즈, 인크. | 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물 |
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CN110540955B (zh) * | 2019-08-28 | 2021-09-17 | 北京协同创新研究院 | 一种提高分化细胞中nrob2基因表达量的方法 |
| ES3014367T3 (en) | 2020-01-15 | 2025-04-22 | Inst Nat Sante Rech Med | Use of fxr agonists for treating an infection by hepatitis d virus |
| EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| WO2022233398A1 (en) * | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| WO2025059651A1 (en) * | 2023-09-14 | 2025-03-20 | The Regents Of The University Of California | Bile salt modification to prevent and treat enteric disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080775A (en) * | 1934-08-22 | 1937-05-18 | Celanese Corp | Shedding mechanism for circular looms |
| US2802775A (en) * | 1953-05-29 | 1957-08-13 | Merck & Co Inc | 11 alpha-hydroxylation of steroids by aspergillus ochraceus |
| JPS59205396A (ja) * | 1983-05-09 | 1984-11-20 | Kuraray Co Ltd | １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法 |
| US6639078B1 (en) | 1998-12-23 | 2003-10-28 | Smithkline Beecham Corporation | Assays for ligands for nuclear receptors |
| ITMI20021532A1 (it) * | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| SI1734970T1 (sl) * | 2004-03-12 | 2015-04-30 | Intercept Pharmaceuticals, Inc. | Zdravljenje fibroze z uporabo FXR ligandov |
| WO2008002573A2 (en) * | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| PT2997035T (pt) | 2013-05-14 | 2018-07-18 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x |
-
2014
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
- 2014-05-14 PE PE2020000355A patent/PE20200844A1/es unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en not_active Ceased
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/en active
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active Active
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
-
2015
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
-
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
-
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
-
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
-
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
-
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
-
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
-
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200844A1 (es) | Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| MX2020003532A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos. | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| UA108221C2 (uk) | Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae | |
| BR112012000763B8 (pt) | compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto | |
| GEP20156351B (en) | Glucagon receptor modulator | |
| CU20100238A7 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR077892A1 (es) | Quinolinas antagonistas de la hepcidina | |
| EA201891261A1 (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний | |
| MX2020005735A (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| EA201591259A1 (ru) | Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |